IntelliCell BioSciences' Stem Cell Technology Validated by Merck Subsidiary
July 14 2011 - 7:00AM
Marketwired
IntelliCell BioSciences, Inc. (OTCQB: SVFC) (PINKSHEETS: SVFC)
("IntelliCell" or the "Company"), a leader in regenerative medicine
and the manufacturing of stromal vascular fraction (SVF) containing
adipose derived adult stem cells, today announced that an antibody
flow cytometry study of IntelliCell's technology was performed by
Millipore, a division of Merck, a life science leader providing
cutting-edge technologies, tools and services for bioscience
research and biopharmaceutical manufacturing.
The results of the study conclude that IntelliCells™
manufactured by IntelliCell's proprietary technology yield an
average of 10 times (10X) the number of SVF cells containing adult
adipose stem cells from less fat (only 2 oz) than that which the
Company believes is used by any of its present competition
utilizing enzymes in their process. The study also showed that
IntelliCells™ contain all of the viable cells that are manufactured
by competing technologies that use enzymatic digestion.
"We believe IntelliCell is setting the gold standard for adipose
stem cell processing without the use of enzymes and yielding high
number of SVFs with adult adipose stem cell counts. We feel that
our technology is a true game changer in the field of regenerative
medicine and that SVF could show incredible promise for a wide
range of clinical uses in the near future," stated IntelliCell
Chairman and CEO, Dr. Steven Victor.
"We believe that the body stores all of the reparative and
regenerative cells it could possibly need as a result of trauma or
illness in the stromal vascular fraction (SVF) contained in the
fat. We are very pleased with the results of Millipore's study as
it does confirm that at least four of these pluripotent stem cell
types are indeed existent in this tissue, and our technology has,
for the very first time in history, unlocked these cells which have
similar potential to embryonic stem cells in their pluripotency, in
vast number, from a source that entails no moral controversy, and
no chemical additives required for digestion of the tissue --
requiring only minimal, mechanical manipulation of the tissue as
defined by the FDA's rule 361," concluded Dr. Steven Victor.
The use of autologous adipose (fat) stem cells has become a new
and exciting frontier in medicine. Numerous doctors, companies and
researchers are studying the use of these adipose stem cells for
applications that include the treatment of arthritis and numerous
orthopedic injuries such as knees, elbows and shoulders; wound
healing; back pain; congestive heart failure; gum recession; and
fat augmentation for breast, buttock and face; as well as other
disease states.
In the aesthetic world, the use of autologous adipose stem cells
has become widely accepted in Europe and Asia. Since the middle of
2009 when the US FDA published its laws on autologous stem cells
the field has expanded rapidly.
IntelliCell has developed an in-house technology where it can
easily process stromal vascular cells containing a high
concentration of adipose stem cells with excellent viability. At
present, management believes it is the only company that does not
use enzymes in processing adipose tissue and actually counts and
checks the adipose stem cells they manufacture.
The adipose stem cell processing technique of IntelliCell takes
approximately 30 minutes and the stem cells can be returned to the
doctor in the same day. Autologous Adipose Stem Cells are on the
cutting edge of medicine and IntelliCell is excited to be one of
the premier companies to participate in this field.
About IntelliCell Biosciences, Inc.
IntelliCell is a pioneering regenerative medicine company
focused on the expanding regenerative medical markets using stromal
vascular fraction derived from adult adipose tissue. IntelliCell
intends to initially focus on setting up tissue processing centers
throughout the United States with managing partners. The centers
will receive and employ the IntelliCell™ process to the adipose
stromal vascular fraction harvested by physicians in their own
offices, and then return the IntelliCells™ to the physicians the
same day labeled "autologous homologous." IntelliCell has already
established processing centers in New York City, Philadelphia,
Dallas/Ft. Worth, and New Orleans, and has entered into a licensing
agreement for a center in Palm Beach. In the future, IntelliCell
intends to pursue expansion to secondary markets and beyond the
U.S. through a combination of company-owned and licensed clinical
facilities. For additional information, visit
http://www.intellicellbiosciences.com or call 212 249 3050.
Forward-Looking Statements
Certain statements set forth in this press release constitute
"forward-looking statements." Forward-looking statements include,
without limitation, any statement that may predict, forecast,
indicate, or imply future results, performance or achievements, and
may contain the words "estimate," "project," "intend," "forecast,"
"anticipate," "plan," "planning," "expect," "believe," "will
likely," "should," "could," "would," "may" or words or expressions
of similar meaning. Such statements are not guarantees of future
performance and are subject to risks and uncertainties that could
cause the company's actual results and financial position to differ
materially from those included within the forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including those relating to the Company's ability to
grow its business. Actual results may differ materially from the
results predicted and reported results should not be considered as
an indication of future performance. The potential risks and
uncertainties include, among others, the Company's limited
operating history, the limited financial resources, domestic or
global economic conditions, activities of competitors and the
presence of new or additional competition, and changes in Federal
or State laws. More information about the potential factors that
could affect the Company's business and financial results is
included in the Company's filings, available via the United States
Securities and Exchange Commission.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: Investor Relations Contact Laurel Moody
646-810-0608 Email Contact